supp.fit

Gotu Kola: study protocols

24 study groups say how much Gotu Kola participants took a day. These are the doses the studies gave. They are not a recommendation.

Gotu Kola: what the research found →

Dose per serving from products

198 products in our catalogue print how much Gotu Kola a serving holds.

Most common: 50 mg to 100 mg, 21% of 198 products.

Dose per servingProducts
5 mg or less
6
5 mg to 10 mg
11
10 mg to 25 mg
10
25 mg to 50 mg
30
50 mg to 100 mg
41
100 mg to 250 mg
30
250 mg to 500 mg
36
500 mg to 1 g
34

Dose per serving from research

24 study groups in 16 studies say how much Gotu Kola participants took a day.

These are the doses the studies gave. They are not a recommendation.

Most common: 100 mg to 250 mg, 63% of 24 study groups.

Daily doseStudy groups
25 mg or less
1
25 mg to 50 mg
1
50 mg to 100 mg
3
100 mg to 250 mg
15
250 mg to 500 mg
2
500 mg to 1 g
1
over 1 g
1

Commonly used together

2 of 24 study groups took Gotu Kola with something else, but nothing that 3 or more different studies gave.

24 study groups

Study
Efficacy of Centella asiatica on mitigating temporomandibular pain and improving functionality: a randomized, double blind, pilot clinical trial
2025 · ECa500 group · Adults aged 18–50 with acute temporomandibular disorder pain lasting 30 days or less
500 mg2 weeks6
Positive modulation of cognition and mood in the healthy elderly volunteer following the administration of Centella asiatica
2008 · 500 mg once-daily group · healthy elderly participants
500 mg60 days—
Positive modulation of cognition and mood in the healthy elderly volunteer following the administration of Centella asiatica
2008 · 750 mg once-daily group · healthy elderly participants
750 mg60 days—
Efficacy of Centella asiatica on mitigating temporomandibular pain and improving functionality: a randomized, double blind, pilot clinical trial
2025 · ECa250 group · Adults aged 18–50 with acute temporomandibular disorder pain lasting 30 days or less
250 mg2 weeks6
Positive modulation of cognition and mood in the healthy elderly volunteer following the administration of Centella asiatica
2008 · 250 mg once-daily group · healthy elderly participants
250 mg60 days—
Comparison of Centella with Flavonoids for Treatment of Symptoms in Hemorrhoidal Disease and After Surgical Intervention: A Randomized Clinical Trial
2020 · Group B (Centella asiatica) · Adults aged 18–85 with hemorrhoidal disease, including chronic disease and patients undergoing procedures
120 mg15 days66
Modification of the echogenicity of femoral plaques after treatment with total triterpenic fraction of Centella asiatica: a prospective, randomized, placebo-controlled trial
2001 · TTFCA treatment group · Adults with hypoechoic atherosclerotic femoral plaques; age and sex not reported
180 mg1 year26
A double-blind, placebo-controlled study on the effects of Gotu Kola (Centella asiatica) on acoustic startle response in healthy subjects
2000 · Gotu Kola · Healthy subjects; age and sex not specified
12 g1 day20
The efficacy and side effects of oral Centella asiatica extract for wound healing promotion in diabetic wound patients
2010 · Centella asiatica extract capsule group · Adults aged 18–80 with diabetes and wounds
150 mg3 weeks—
Long-term follow-up of oral administration of flavonoids, Centella asiatica and Melilotus, for diabetic cystoid macular edema without macular thickening
2013 · treatment group · Patients with type 2 diabetes and diabetic cystoid macular edema without macular thickening
15 mg3 years35
Combination of flavonoids with Centella asiatica and Melilotus for diabetic cystoid macular edema without macular thickening
2011 · treatment group · Patients with type 2 diabetes and diabetic cystoid macular edema without macular thickening; age and sex not specified
30 mg426 days20
Evaluation of treatment of diabetic microangiopathy with total triterpenic fraction of Centella asiatica: a clinical prospective randomized trial with a microcirculatory model
2001 · TTFCA-treated group · Patients with diabetic microangiopathy
120 mg26 weeks30
Effects of the total triterpenic fraction of Centella asiatica in venous hypertensive microangiopathy: a prospective, placebo-controlled, randomized trial
2001 · treatment group · Adults with severe venous hypertension, ankle swelling, and lipodermatosclerosis; mean age 48 years
120 mg8 weeks22
Microcirculatory effects of total triterpenic fraction of Centella asiatica in chronic venous hypertension: measurement by laser Doppler, TcPO2-CO2, and leg volumetry
2001 · treatment group · Adults with venous hypertension; mean age 42 years; 10 women and 10 men
120 mg6 weeks20
Treatment of edema and increased capillary filtration in venous hypertension with total triterpenic fraction of Centella asiatica: a clinical, prospective, placebo-controlled, randomized, dose-ranging trial
2001 · Group A · Patients with venous hypertension (ambulatory venous pressure >42 mm Hg)
180 mg4 weeks20
Treatment of edema and increased capillary filtration in venous hypertension with total triterpenic fraction of Centella asiatica: a clinical, prospective, placebo-controlled, randomized, dose-ranging trial
2001 · Group B · Patients with venous hypertension (ambulatory venous pressure >42 mm Hg)
90 mg4 weeks20
Pharmacokinetics of the total triterpenic fraction of Centella asiatica after single and multiple administrations to healthy volunteers. A new assay for asiatic acid
1990 · 30 mg twice-daily treatment for 7 days · healthy volunteers; age and sex not reported
60 mg7 days12
Pharmacokinetics of the total triterpenic fraction of Centella asiatica after single and multiple administrations to healthy volunteers. A new assay for asiatic acid
1990 · 60 mg twice-daily treatment for 7 days · healthy volunteers; age and sex not reported
120 mg7 days12
Treatment of edema and increased capillary filtration in venous hypertension with total triterpenic fraction of Centella asiatica: a clinical, prospective, placebo-controlled, randomized, dose-ranging trial
2001 · Group D · Normal subjects
180 mg4 weeks10
Increase in echogenicity of echolucent carotid plaques after treatment with total triterpenic fraction of Centella asiatica: a prospective, placebo-controlled, randomized trial
2001 · TTFCA-treated group (Part I pilot study) · Patients with carotid plaques; age and sex not stated
180 mg1 year—
Increase in echogenicity of echolucent carotid plaques after treatment with total triterpenic fraction of Centella asiatica: a prospective, placebo-controlled, randomized trial
2001 · TTFCA treatment group (Part II) · Asymptomatic patients with hypoechoic-echolucent carotid plaques (GSM<18); age and sex not stated
180 mg1 year—
Treatment of diabetic microangiopathy and edema with total triterpenic fraction of Centella asiatica: a prospective, placebo-controlled randomized study
2001 · TTFCA treatment group · Patients with diabetic microangiopathy, with or without neuropathy; the abstract does not report their age or sex.
120 mg1 year—
[The microcirculatory activity of Centella asiatica in venous insufficiency. A double-blind study]
1994 · 30 mg bid · Patients with chronic venous hypertensive microangiopathy
60 mg60 days—
[The microcirculatory activity of Centella asiatica in venous insufficiency. A double-blind study]
1994 · 60 mg bid · Patients with chronic venous hypertensive microangiopathy
120 mg60 days—